1. The antibody aducanumab reduces A? plaques in Alzheimer's disease.

    Nature 537(7618):50 (2016) PMID 27582220

    Alzheimer's disease (AD) is characterized by deposition of amyloid-_ (A_) plaques and neurofibrillary tangles in the brain, accompanied by synaptic dysfunction and neurodegeneration. Antibody-based immunotherapy against A_ to trigger its clearance or mitigate its neurotoxicity has so far been uns...
  2. Amyloid PET Screening for Enrichment of Early-Stage Alzheimer Disease Clinical Trials: Experience in a Phase 1b Clinical Trial.

    Alzheimer Disease and Associated Disorders 30(1):1 (2016) PMID 26885819

    Amyloid positron emission tomography (PET) imaging is being investigated as a screening tool to identify amyloid-positive patients as an enrichment strategy for Alzheimer disease (AD) clinical trial enrollment. In a multicenter, phase 1b trial, patients meeting clinical criteria for prodromal or...
  3. ENRICHMENT OF EARLY-STAGE AD PATIENT RECRUITMENT TO A PHASE IB STUDY (221AD103) THROUGH AMYLOID PET SCREENING BY APOE ɛ4 STATUS

    Alzheimer's & Dementia 10(4):P263 (2014)

  4. OPTIMIZED, FULLY-AUTOMATED CLASSIFICATION OF AMYLOID-POSITIVE SUBJECTS BASED ON [18F]FLORBETAPIR PET SCANS

    Alzheimer's & Dementia 10(4):P708 (2014)

  5. CONCORDANCE OF QUANTITATIVE SUVR METHODS WITH VISUAL ASSESSMENT OF FLORBETAPIR PET SCREENING RESULTS

    Alzheimer's & Dementia 10(4):P399 (2014)

  6. Advances in active and passive immunotherapy for Alzheimer's disease

    Neurobiology of Aging 35:S10 (2014)

  7. Pharmacokinetics of BIIB037 in people with mild-to-moderate Alzheimer's disease (AD) participating in a phase 1 dose-escalation trial

    Alzheimer's & Dementia 9(4):P285 (2013)

  8. Amyloid PET screening results by APOE-ε4 status from a phase 1b clinical study of 221AD103 in people with prodromal to mild Alzheimer's disease

    Alzheimer's & Dementia 9(4):P291 (2013)

  9. Amyloid PET screening for enrollment into Alzheimer's disease clinical trials: An effective enrichment strategy in a phase 1b clinical trial

    Alzheimer's & Dementia 9(4):P249 (2013)

  10. Effects of body weight on tolerability of rivastigmine transdermal patch: a post-hoc analysis of a double-blind trial in patients with Alzheimer disease.

    Alzheimer Disease and Associated Disorders 25(1):58 (2011) PMID 20975519

    The rationale for the development of the rivastigmine transdermal patch was to improve upon an efficacious therapy by mitigating certain adverse events, such as nausea and vomiting. This may be particularly important in Alzheimer disease patients with low body weights, who may be more susceptibl...